Basilicata

Basilicata

Authors

  • Maria Caterina Cavallo Università Bocconi, Milano
  • Filippo Cipriani GlaxoSmithKline Spa, Verona
  • Simone Gerzeli Dipartimento di Statistica ed Economia Applicate L. Lenti, Università di Pavia
  • Nadia Demarteau GlaxoSmithKline Biologicals, Wavre (Belgio)
  • Alessia Marocco GlaxoSmithKline Spa, Verona
  • Francesco Bamfi GlaxoSmithKline Spa, Verona

DOI:

https://doi.org/10.7175/fe.v9i1S.1016

Keywords:

Basilicata, HPV vaccination, Economic & clinical impact

Abstract

In Basilicata region 57,5% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 14 cases of cervicocarcinoma and 6 related deaths and thus results to be cost-effective (20.169 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 15 cancer cases and 6 deaths could be prevented, with a very similar cost-effectiveness ratio. In Basilicata region, the net cost for woman vaccinated is 185 € for the single cohort and 189 € for the multiple cohort.

Downloads

Published

2008-09-15

How to Cite

Cavallo, M. C., Cipriani, F., Gerzeli, S., Demarteau, N., Marocco, A., & Bamfi, F. (2008). Basilicata. Farmeconomia. Health Economics and Therapeutic Pathways, 9(1S), 79–81. https://doi.org/10.7175/fe.v9i1S.1016

Issue

Section

Supplement

Similar Articles

<< < 4 5 6 7 8 9 10 11 12 13 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >> 
Loading...